Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cellectis

- PMLiVE

AstraZeneca’s heart drug impresses, but bleeding risks a concern

Firm still hopes the new Brilinta data can help the medicine be a blockbuster

- PMLiVE

AstraZeneca bullish on diabetes franchise fortunes

Other big pharma firms face a difficult 2015, but AZ is confident it won't

- PMLiVE

Novartis and GSK complete oncology and vaccines swap

Follows Swiss company's decision to divest its BRAF and MEK inhibitors to Array BioPharma

- PMLiVE

AZ gets injunction to protect Pulmicort Respules

Actavis blocked from selling generic five days after AZ’s asthma launch

- PMLiVE

Merck takes promotional responsibility for Erbitux in Japan

Currently co-promotes the drug withBristol-Myers Squibb

- PMLiVE

Takeda’s lung cancer drug motesanib flunks another trial

Drug was unable to extend progression-free survival in study of 400 patients

EISAI

Eisai given early approval for new oncology drug

Japanese firm’s thyroid cancer treatment Lenvimaset to be a blockbuster

- PMLiVE

AstraZeneca employs Wolfram tech for liver health research

Project could produce mathematical models that can detect liver problems

- PMLiVE

MedImmune partners with university on protein formulation science

Four-year partnership to research antibodies and novel proteins

- PMLiVE

AZ adds to respiratory portfolio with Actavis drugs

Follows deal to acquire Almirall’s franchise in asthma and COPD

- PMLiVE

AZ and University of Texas to collaborate on cancer research

Studies will aim to improve patient outcomes

- PMLiVE

Pfizer’s Ibrance wins early breast cancer approval in US

FDA’s decision come two months ahead of schedule

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links